Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis

INTRODUCTION: Maximizing responses of malignant gliomas is hampered by resistance to temozolomide (TMZ). Increasing efficacy but not toxicity is a key issue when testing drug combinations. The antimyeloma agent bortezomib (BZ) has shown promising results in vitro and is currently being tested in gli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arch Med Sci
Autors principals: Vlachostergios, Panagiotis J., Papandreou, Christos N.
Format: Artigo
Idioma:Inglês
Publicat: Termedia Publishing House 2013
Matèries:
Basic Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424237/
https://ncbi.nlm.nih.gov/pubmed/25995745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2013.36919
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars